B. Riley Boosts Lantheus (NASDAQ:LNTH) Price Target to $99.00

Lantheus (NASDAQ:LNTH - Get Free Report) had its price objective upped by analysts at B. Riley from $95.00 to $99.00 in a report released on Thursday, Benzinga reports. The firm presently has a "buy" rating on the medical equipment provider's stock. B. Riley's price target would indicate a potential upside of 58.83% from the company's previous close.

Other research analysts have also issued research reports about the stock. JMP Securities restated a "market outperform" rating and issued a $100.00 price target on shares of Lantheus in a research report on Friday, February 23rd. Truist Financial reissued a "buy" rating and set a $82.00 target price (up from $80.00) on shares of Lantheus in a research note on Monday, February 26th. Finally, StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Saturday, January 13th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $104.71.

Lantheus Price Performance

Lantheus stock traded up $0.85 during mid-day trading on Thursday, hitting $62.33. The company's stock had a trading volume of 1,271,292 shares, compared to its average volume of 1,062,508. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $4.27 billion, a P/E ratio of 13.62 and a beta of 0.53. Lantheus has a twelve month low of $50.20 and a twelve month high of $100.85. The stock's fifty day moving average price is $60.52 and its two-hundred day moving average price is $63.00.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.33 by $0.26. The firm had revenue of $354.00 million for the quarter, compared to analyst estimates of $350.44 million. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. Research analysts forecast that Lantheus will post 5.72 earnings per share for the current year.

Insider Buying and Selling at Lantheus

In other news, Director Mary Anne Heino sold 93,863 shares of the business's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the transaction, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction dated Wednesday, March 6th. The shares were acquired at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the acquisition, the insider now directly owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mary Anne Heino sold 93,863 shares of the business's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the transaction, the director now owns 251,643 shares in the company, valued at $16,434,804.33. The disclosure for this sale can be found here. Insiders have sold a total of 94,545 shares of company stock valued at $6,169,936 in the last three months. 1.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Lantheus

Institutional investors and hedge funds have recently modified their holdings of the stock. Tucker Asset Management LLC boosted its holdings in Lantheus by 239.0% in the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 282 shares in the last quarter. Principal Securities Inc. bought a new stake in Lantheus in the fourth quarter worth $28,000. First Horizon Advisors Inc. boosted its holdings in Lantheus by 97.0% in the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider's stock worth $32,000 after purchasing an additional 225 shares in the last quarter. West Tower Group LLC boosted its holdings in Lantheus by 534.1% in the fourth quarter. West Tower Group LLC now owns 520 shares of the medical equipment provider's stock worth $32,000 after purchasing an additional 438 shares in the last quarter. Finally, Parkside Financial Bank & Trust boosted its holdings in Lantheus by 60.2% in the second quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider's stock worth $36,000 after purchasing an additional 160 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.